GlobalData on MSN

HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir

Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.
Forbes

A New Strategy May Finally Put An HIV Vaccine Within Reach

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...

Progress and Possibility in HIV Prevention

HIV doesn’t discriminate, but societal barriers have left Black Americans disproportionately affected. HIV prevention options ...
Hawai‘i Public Radio

'People are still afraid of those three letters': Fighting the stigma of HIV

That's a quote from former rugby star Gareth Thomas, who is HIV positive. At the International AIDS Conference in Rio this ...
CNBC

Gilead says its twice-yearly shot cut HIV infections by 96% in trial

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3 ...
Forbes

Breakthrough HIV Drug Is Out Of Reach For Many Who Need It Most

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. NAKURU, KENYA - 2026/03/26: A healthcare worker fills a syringe with a dose of lenacapavir, ...
The New England Journal of Medicine

Advanced HIV as a Neglected Disease

In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the ...

HIV Prevention Falters as Funding Cuts Hit PrEP Treatment Access

Global efforts to prevent HIV lost ground last year as funding disruptions forced countries to scale back services, even as ...